Alto Neuroscience Inc

ANRONYSE · USD
27.12USD0.00 (-8.20%)
2510

Alto Neuroscience Inc (ANRO) Covered Calls

Alto Neuroscience Inc trades in the Biotechnology industry with an IV Rank of 19.44%, low versus the past year. ANRO's highest covered call setup is the $45.00 strike expiring Apr 16, 2027, sorted by theoretical annualized return. It's 65.93% out of the money with 151 days to expiration, a 66.67% return until expiration, and a 161.15% theoretical annualized return. Across the setups shown, annualized returns run from 53.30% to 161.15% at strikes between $30.00 and $45.00, with 32 to 151 days to expiration, as of Nov 16, 2026.

Read more

Running ANRO covered calls helps you generate income from Alto Neuroscience Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ANRO covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ANRO stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ANRO covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ANRO covered call is worth writing.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD.

2027-04-1615145.0065.930.204.901808.0066.67161.15-0.74+0.3224.70
2026-12-183230.0010.620.604.90348.0012.83146.36-2.21+0.4604.30
2027-04-1615140.0047.490.305.001318.0048.60117.47-1.11+0.35104.70
2027-01-156030.0010.622.353.40523.0019.28117.32-8.67+0.47421.05
2027-04-1615135.0029.061.205.50908.0033.4880.93-4.42+0.4214.30
2027-04-1615130.0010.623.107.50598.0022.0553.30-11.43+0.56664.40

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank19.44% Low
  • Market cap (M$)1,088
  • 52 weeks high-27.64%
  • 52 weeks low116.79%
  • Analyst recommendationStrong Buy
    1.27
  • Target price$38.88
    43.36% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-10
  • P/E—
  • Future P/E—
  • EPS (ttm)-2.49
  • EPS growth next 5 years-9.01%

As of Nov 16, 2026